Viewing Study NCT07176650

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 5:25 PM
Ignite Modification Date: 2026-02-20 @ 6:42 PM
Study NCT ID: NCT07176650
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-09-16
First Post: 2025-09-01
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Sponsor: Shanghai Henlius Biotech
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Hepatocellular Carcinoma (HCC) View
Keywords: